MAPK8 and diabetes mellitus: Numerous JNK pathway inhibitors have been entered into preclinical and clinical trials as potential therapies for diabetes, cancer, depression, neurotrauma, hearing loss, and even Alzheimer’s disease, exhibiting a future perspective in the context of many disease therapies [9,15,103,104,105,106].